Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

40.52USD
15 Dec 2017
Change (% chg)

$0.51 (+1.27%)
Prev Close
$40.01
Open
$40.32
Day's High
$40.78
Day's Low
$39.22
Volume
4,837,634
Avg. Vol
2,206,354
52-wk High
$45.86
52-wk Low
$29.44

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $21,730.10
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

Perrigo lines up bid for Merck's consumer health unit: sources

LONDON/FRANKFURT Generic drugmaker Perrigo has decided to enter the fray for Merck KGaA's consumer health unit, sources told Reuters, and is preparing an indicative offer for the $4.7 billion business ahead of a deadline on Friday.

Dec 14 2017

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

* MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS

Dec 14 2017

BRIEF-Mylan Says Teva Has Dismissed Its Pending Litigation Against Co

* MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN

Dec 11 2017

BRIEF-Mylan And Aspen Announce Launch Of Generic Busulfex Injection

* MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION

Dec 04 2017

Indian shares rise; Infosys jumps as CEO appointment brings peace hopes

Dec 4 Indian stocks rose on Monday as Infosys Ltd rallied on hopes that the appointment of a new CEO would help the company move on from a feud between its board and founders that had pummelled shares.

Dec 04 2017

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

Dec 01 2017

UPDATE 3-FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

* Approval ups confidence in Mylan's biosimilar efforts -analysts

Dec 01 2017

BRIEF-FDA Approves Mylan's Heparin Sodium Injection

* FDA APPROVAL OF HEPARIN SODIUM INJECTION CONTINUES TO DEMONSTRATE MYLAN'S DEEP EXPERTISE IN DEVELOPING COMPLEX PRODUCTS

Dec 01 2017

FDA approves Mylan's biosimilar of Roche's breast cancer treatment

Dec 1 The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster breast cancer treatment Herceptin.

Dec 01 2017

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

Nov 30 2017

Earnings vs. Estimates